Deciphering metabonomics biomarkers-targets interactions for psoriasis vulgaris by network pharmacology
Objectives: Psoriasis vulgaris is a chronic inflammatory and immune-mediated skin disease. 44 metabonomics biomarkers were identified by high-throughput liquid chromatography coupled to mass spectrometry in our previous work, but the roles of metabonomics biomarkers in the pathogenesis of psoriasis is unclear.
Methods: The metabonomics biomarker-enzyme network was constructed. The key metabonomics biomarkers and enzymes were screened out by network analysis. The binding affinity between each metabonomics biomarker and target was calculated by molecular docking. A binding energy-weighted polypharmacological index was introduced to evaluate the importance of target-related pathways.
Results: Long-chain fatty acids, phospholipids, Estradiol and NADH were the most important metabonomics biomarkers. Most key enzymes belonged hydrolase, thioesterase and acyltransferase. Six proteins (TNF-alpha, MAPK3, iNOS, eNOS, COX2 and mTOR) were extensively involved in inflammatory reaction, immune response and cell proliferation, and might be drug targets for psoriasis. PI3K-Akt signaling pathway and five other pathways had close correlation with the pathogenesis of psoriasis and could deserve further research.
Conclusions: The inflammatory reaction, immune response and cell proliferation are mainly involved in psoriasis. Network pharmacology provide a new insight into the relationships between metabonomics biomarkers and the pathogenesis of psoriasis.KEY MESSAGES
• Network pharmacology was adopted to identify key metabonomics biomarkers and enzymes.
• Six proteins were screened out as important drug targets for psoriasis.
• A binding energy-weighted polypharmacological index was introduced to evaluate the importance of target-related pathways.
• Network pharmacology was adopted to identify key metabonomics biomarkers and enzymes.
• Six proteins were screened out as important drug targets for psoriasis.
• A binding energy-weighted polypharmacological index was introduced to evaluate the importance of target-related pathways.
